Jay Luly, Enanta Pharmaceuticals CEO
May 9, 2023 06:15 AM EDT
Coronavirus

Enan­ta is look­ing for a part­ner on its Covid pill af­ter a PhII study dis­ap­points

Ryan Cross

Senior Science Correspondent

A biotech com­pa­ny with am­bi­tions to com­pete with Pfiz­er’s block­buster Covid-19 pill an­nounced mixed re­sults from a study of its ex­per­i­men­tal an­tivi­ral ther­a­py and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times